ArticleJournal of virology2025
Interferon-stimulated gene MCL1 inhibits foot-and-mouth disease virus replication by modulating mitochondrial dynamics and autophagy.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intralesional Interferon Alfa-2b Versus Cryotherapy for Common Warts on the Hands and Feet: A Randomized, Open-Label, Controlled Trial.Journal of cosmetic dermatology · 2026Trial
- The Dual Roles of Autophagy in Important Picornaviruses Infecting Livestock and Poultry.Veterinary sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Interferons (IFNs) and the IFN-stimulated genes (ISGs) that they induce are effective in reducing the replication of foot and mouth disease virus (FMDV). The use of a high-throughput ISG screen identified the ISG myeloid cell leukemia 1 (MCL1) as an ISG with an antiviral effect against an FMDV replicon system. In this study, we demonstrated that overexpression of MCL1 inhibits FMDV replication by reducing approximately 4 logs of virus titers in porcine cells. We then explored the regulatory pathways associated with MCL1 to determine the specific antiviral mechanisms against FMDV. Our findings indicated that the antiviral mechanism does not involve apoptosis regulation or alterations in cell cycle phase heterogeneity. Analysis of mitochondrial function, through measurement of mitochondrial oxygen consumption rate, demonstrated that overexpression of MCL1 results in increased mitochondrial respiration and ATP production, whereas FMDV infection reduces both processes. Moreover, MCL1 overexpression resulted in elongated mitochondrial morphology, contrasting with the fragmented and punctate morphology observed during FMDV infection. Importantly, these changes in mitochondrial dynamics were independent of MCL1's regulation of mitochondrial calcium flux. We also found that MCL1 overexpression suppresses autophagy, which is known to be necessary for FMDV replication. Our data indicate that MCL1 is a potent antiviral ISG against FMDV and highlight the importance of mitochondrial dynamics and autophagy in FMDV replication.IMPORTANCEIn this study, we have successfully used a high-throughput ISG screening approach to measure the inhibition of FMDV replication using an RNA replicon system for the first time. This screen led to the identification of the potent antiviral effects of a relatively lesser-known ISG called MCL1. Our findings reveal that MCL1 exerts its antiviral functions through the regulation of mitochondrial dynamics and autophagy. Although mitochondrial dynamics are involved in apoptosis, metabolism, redox homeostasis, stress responses, and antiviral signaling, this pathway has not been thoroughly explored in the context of FMDV infection. Further investigation into mitochondrial dynamics may facilitate the development of improved biotherapeutics for FMDV. Additionally, our studies highlight the significance of autophagy, a pathway that is needed by FMDV for replication. Ultimately, a deep understanding of all mechanisms exploited by FMDV may allow for the rational design of novel therapeutics and vaccines to control FMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.